# EDGAR Filing Document

**Accession Number:** 0000064803
**File Stem:** 0000947871-23-000080
**Filing Date:** 2023-1
**Character Count:** 10255
**Document Hash:** 301a6b24c50212aaab7f97a7d6b9a9c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-23-000080.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0000947871-23-000080

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230118

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CVS HEALTH Corp
- **CENTRAL INDEX KEY:** 0000064803
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **IRS NUMBER:** 050494040
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-01011
- **FILM NUMBER:** 23544616

**BUSINESS ADDRESS:**
- **STREET 1:** ONE CVS DR.
- **CITY:** WOONSOCKET
- **STATE:** RI
- **ZIP:** 02895
- **BUSINESS PHONE:** 4017651500

**MAIL ADDRESS:**
- **STREET 1:** ONE CVS DR.
- **CITY:** WOONSOCKET
- **STATE:** RI
- **ZIP:** 02895

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS CAREMARK CORP
- **DATE OF NAME CHANGE:** 20070509

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS/CAREMARK CORP
- **DATE OF NAME CHANGE:** 20070322

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CVS CORP
- **DATE OF NAME CHANGE:** 19970128

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

---

| | |
|:---|:---|
| Date of Report (Date of earliest event reported): | **January 23, 2023 (January 18, 2023)** |

---

![](image_001.jpg)

**CVS HEALTH CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-01011** | **05-0494040** |
| (State or other jurisdiction of incorporation) | (Commission <br> File Number) | (IRS Employer <br> Identification No.) |

---

**One CVS Drive, Woonsocket, Rhode Island&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;02895**

(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Zip Code)

Registrant's telephone number, including area code: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(401) 765-1500**

Former name or former address, if changed since last report:&nbsp;&nbsp;&nbsp;&nbsp;**N/A**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | CVS | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | |
|:---|:---|
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

**Section 5 - Corporate Governance and Management** 

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 18, 2023, Alan M. Lotvin, M.D., Executive Vice President and President, Pharmacy Services, advised CVS Health Corporation of his intention to retire in April 2023.

**Section 7 - Regulation FD**

**Item 7.01 Regulation FD Disclosure.**

On January 23, 2023, CVS Health Corporation announced that it has appointed J. David Joyner as its new President, Pharmacy Services, effective January 30, 2023.

On January 23, 2023, CVS Health Corporation issued a press release announcing Dr. Lotvin's retirement, described in Item 5.02 above, and Mr. Joyner's appointment. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 7.01 by reference.

The information in this Item 7.01 of this Current Report on Form 8-K and the press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Section 9 - Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits.**

**(d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Exhibits</u>.**

The exhibits to this Current Report on Form 8-K are as follows:

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| [99.1](ss1693564_ex9901.htm) | [Press Release of CVS Health Corporation, dated January 23, 2023](ss1693564_ex9901.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **CVS HEALTH CORPORATION** |
| Date: January 23, 2023 | By: | /s/ Colleen M. McIntosh |
|  |  | Colleen M. McIntosh |
|  |  | Senior Vice President, Secretary and<br> Chief Governance Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**PRESS RELEASE**<br>

**CVS Health Names David Joyner Head of Pharmacy Services;**

**Amy Bricker Becomes Chief Product Officer - Consumer**

WOONSOCKET, R.I., Jan. 23, 2023 — CVS Health® (NYSE: <u>CVS</u>) today announced two executive appointments. David Joyner will rejoin the company as Executive Vice President and President of Pharmacy Services, while Amy Bricker has been named Executive Vice President and Chief Product Officer - Consumer.

"David and Amy are accomplished leaders with proven track records of anticipating and meeting customer and client needs," said CVS Health President and CEO Karen S. Lynch. "David has deep experience in pharmacy benefit management that will help us deliver on our growth strategy for the business."

Joyner will join the company on January 30 and lead the Pharmacy Services segment, which provides solutions to employers, health plans, and government businesses and serves more than 110 million members through CVS Caremark®, CVS Specialty® and other areas. He will become a member of the company's executive leadership team and report to Lynch. Joyner, a former CVS Health executive, brings more than 34 years of health care and pharmacy benefit management experience to the company.

"CVS Caremark is a pharmacy innovator, consistently delivering industry leading products and results for customers," said Joyner. "I look forward to working alongside a talented team dedicated to improving the health care experience."

Joyner replaces Dr. Alan Lotvin, who plans to retire in April. Dr. Lotvin has played a critical role in the growth and success of several CVS Health businesses over the course of his 10-year tenure. He has been a champion of affordable and accessible health care, previously serving as head of CVS Specialty and as Chief Transformation Officer.

Bricker will join the company in February, serving on the company's executive leadership team and reporting to Lynch in a newly created role. Bricker has nearly 20 years of diverse health care experience, most recently serving as President of Express Scripts.

"Every element of our strategy puts consumers first with a particular focus on the products and services they use to stay well," said Lynch. "Amy's passion and proven leadership will be invaluable assets as we continue to deliver on that strategy."

Bricker will focus on consumer products and innovation, leading the development of new products that support the evolving health care needs of consumers in the community, the home, and digitally.

"CVS Health has unmatched opportunities to enhance and launch consumer products that make care simpler and more affordable," said Bricker. "I'm incredibly excited to join the company at a pivotal time in health care."

###

**About CVS Health**

<u>CVS Health</u>® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

**Media contact**<br> T.J. Crawford<br> 212-457-0583<br> CrawfordT2@CVSHealth.com

**Investor contact**<br> Larry McGrath<br> 800-201-0938<br> InvestorInfo@CVSHealth.com